Justin Trojanowski - Tempest Therapeutics Treasurer Controller
| TPST Stock | USD 0.93 0.03 3.33% |
Insider
Justin Trojanowski is Treasurer Controller of Tempest Therapeutics
| Age | 36 |
| Address | 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
| Phone | 415 798 8589 |
| Web | https://www.tempesttx.com |
Latest Insider Transactions
Justin Trojanowski Latest Insider Activity
Tracking and analyzing the buying and selling activities of Justin Trojanowski against Tempest Therapeutics stock is an integral part of due diligence when investing in Tempest Therapeutics. Justin Trojanowski insider activity provides valuable insight into whether Tempest Therapeutics is net buyers or sellers over its current business cycle. Note, Tempest Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tempest Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Justin Trojanowski over six months ago Acquisition by Justin Trojanowski of 7500 shares of Tempest Therapeutics at 2.16 subject to Rule 16b-3 | ||
Justin Trojanowski over a year ago Acquisition by Justin Trojanowski of 55000 shares of Tempest Therapeutics subject to Rule 16b-3 |
Tempest Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7701) % which means that it has lost $0.7701 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9189) %, meaning that it created substantial loss on money invested by shareholders. Tempest Therapeutics' management efficiency ratios could be used to measure how well Tempest Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2025. Return On Capital Employed is likely to drop to -0.83 in 2025. Liabilities And Stockholders Equity is likely to gain to about 70.9 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 9.6 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| David Myles | Olema Pharmaceuticals | 62 | |
| Ray MD | Akari Therapeutics PLC | 79 | |
| Duane BA | Armata Pharmaceuticals | 74 | |
| Brian MD | Rezolute | 50 | |
| Walt Esq | Indaptus Therapeutics | 64 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Robert Floyd | Processa Pharmaceuticals | 68 | |
| Courtney Dugan | Olema Pharmaceuticals | N/A | |
| PharmD Young | Processa Pharmaceuticals | 72 | |
| PharmD Faltaos | Olema Pharmaceuticals | N/A | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Peter Kushner | Olema Pharmaceuticals | 85 | |
| Adam Levy | Zentalis Pharmaceuticals Llc | N/A | |
| Path FRCP | Revolution Medicines | 61 | |
| Kevin Bunker | Zentalis Pharmaceuticals Llc | 52 | |
| David Pompliano | Revolution Medicines | N/A | |
| John Castle | Monte Rosa Therapeutics | 54 | |
| Ronald CPA | RenovoRx | N/A | |
| Wenyuan Shi | Armata Pharmaceuticals | N/A | |
| Angela Nelms | RenovoRx | 47 | |
| Melissa MBA | Zentalis Pharmaceuticals Llc | 45 | |
Management Performance
| Return On Equity | -6.92 | ||||
| Return On Asset | -0.77 |
Tempest Therapeutics Leadership Team
Elected by the shareholders, the Tempest Therapeutics' board of directors comprises two types of representatives: Tempest Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tempest. The board's role is to monitor Tempest Therapeutics' management team and ensure that shareholders' interests are well served. Tempest Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tempest Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Justin CPA, Treasurer Controller | ||
| Dr Dubensky, Pres Director | ||
| Justin Trojanowski, Treasurer Controller | ||
| Nicholas Maestas, VP Secretary | ||
| RAC Sakai, Head Quality | ||
| Samuel MD, Executive Officer | ||
| Petpiboon Prasit, Acting Director | ||
| Anne Moon, Project Leadership | ||
| LLM JD, President CEO | ||
| Lindsay Young, Head Resources |
Tempest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tempest Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.92 | ||||
| Return On Asset | -0.77 | ||||
| Current Valuation | 36.21 M | ||||
| Shares Outstanding | 43.64 M | ||||
| Shares Owned By Insiders | 0.16 % | ||||
| Shares Owned By Institutions | 15.53 % | ||||
| Number Of Shares Shorted | 2.6 M | ||||
| Price To Earning | 0.23 X | ||||
| Price To Book | 3.54 X | ||||
| EBITDA | (28.78 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.